Efatutazone
- Generic Name
- Efatutazone
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C27H26N4O4S
- CAS Number
- 223132-37-4
- Unique Ingredient Identifier
- M17ILL71MC
- Background
Efatutazone has been used in trials studying the treatment of Lymphoma, Liposarcoma, Solid Tumors, Multiple Myeloma, and Recurrent Thyroid Cancer, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery
- First Posted Date
- 2014-09-26
- Last Posted Date
- 2023-06-07
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 15
- Registration Number
- NCT02249949
- Locations
- ๐บ๐ธ
Northside Hospital, Atlanta, Georgia, United States
๐บ๐ธRush - Copley Medical Center, Aurora, Illinois, United States
๐บ๐ธIllinois CancerCare-Canton, Canton, Illinois, United States
Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-06-02
- Last Posted Date
- 2023-04-27
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 19
- Registration Number
- NCT02152137
- Locations
- ๐บ๐ธ
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
๐บ๐ธMinor and James Medical PLLC, Seattle, Washington, United States
๐บ๐ธSwedish Medical Center-Cherry Hill, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
ยฉ Copyright 2024. All Rights Reserved by MedPath